[ad_1]
Vaxtex Cotfab (NSE:VCL) Third Quarter 2023 Results
Key Financial Results
- Revenue: ₹113.9m (down 53% from 3Q 2022).
- Net income: ₹890.0k (up from ₹542.6k loss in 3Q 2022).
- Profit margin: 0.8% (up from net loss in 3Q 2022).
- EPS: ₹0.02 (up from ₹0.011 loss in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Vaxtex Cotfab shares are down 6.4% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we’ve spotted 5 warning signs for Vaxtex Cotfab you should be aware of, and 3 of them make us uncomfortable.
Valuation is complex, but we’re helping make it simple.
Find out whether Vaxtex Cotfab is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
[ad_2]
Source link
